Jump to content

Balovaptan

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 20:30, 2 April 2016 (Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Balovaptan

RG7314 is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of autism.[1] As of August 2014, it is in phase II clinical trials for this indication.[2]

See also

References

  1. ^ "Roche - Pipeline". 2014. Retrieved 2014-08-01.
  2. ^ A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders, at ClinicalTrials.gov; retrieved September 2, 2014


Template:Neuropeptidergics


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Balovaptan&oldid=713237529"